Is Omeros Corp (OMER) a Stock to Watch After Losing -6.35% This Week?

The market has been down on Omeros Corp (OMER) stock recently. OMER gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Omeros Corp has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on OMER!

See Full OMER Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With OMER Stock Today?

Omeros Corp (OMER) stock has risen 2.44% while the S&P 500 is down -0.14% as of 11:54 AM on Wednesday, Mar 13. OMER is up $0.10 from the previous closing price of $4.03 on volume of 137,312 shares. Over the past year the S&P 500 has gained 34.03% while OMER is up 19.71%. OMER earned $0.32 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 12.88. To see InvestorsObserver's Sentiment Score for Omeros Corp click here.

More About Omeros Corp

Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders. Click Here to get the full Stock Report for Omeros Corp stock.